The revisions balance a growing understanding of gender identity disorders and societal views with the need to retain conditions that benefit from intervention and the removal of which would hamper patients’ ability to receive medical treatment.
Theodore E. Schall, PhD, MSW, MBE, Kaitlyn Jaffe, PhD, and Jacob D. Moses, PhD
Clinicians should know how randomized controlled trials can and cannot contribute to advancing health equity for transgender and gender diverse people.
AMA J Ethics. 2024;26(9):E684-689. doi:
10.1001/amajethics.2024.684.